Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of IMCR is 69 and suggests 108% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell